Europe: Recent development in SPCs
Managing IP is part of the Delinian Group, Delinian Limited, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Europe: Recent development in SPCs

Supplementary protection certificates (SPCs) are issued under EU Regulation 469/2009 to compensate for lost patent time because of the pharmaceutical marketing authorisation procedure.

According to Article 3 of the Regulation, an extended protection may be provided for basic patents covering the product for which the first marketing authorization (MA) has been obtained. In national proceedings where the validity of SPCs is questioned, the courts may refer questions on interpretation of the Regulation to the Court of Justice of the EU (CJEU). In the recent past, however, the CJEU has not been applauded for its clear and concise rulings on this matter.

Recently, three new decisions have been issued by the CJEU on how to interpret Article 3. In C-493/12 (HGS v Eli Lilly) some light was shed on the question when a product is covered by a patent. It was explained by the CJEU that is not sufficient to argue that the product infringes the patent, but on the other hand neither is it deemed necessary that the active ingredient be identified by a specific formula in the patent. What exactly is required to satisfy the criterion according to the CJEU is still a matter of speculation.

Another question that was pending is whether a compound protected by one patent can give rise to two different SPCs (if the compound would have two different market authorisations). This was the case in C-443/12 between Actavis and Sanofi, where Sanofi had obtained an SPC for irbesartan and a combination of irbesartan with the diuretic HCTZ. The CJEU argued that in principle it could be possible to have multiple SPCs for products covered by one patent if these products are covered by the patent. However, in this case the CJEU ruled that the second SPC (on the combination) was invalid because the first SPC already protected irbesartan, no matter whether it was marketed as single product or in the combination (where it was present for the same indication).

Relating to this, but approaching from a different angle, is C-484/12 (Georgetown II) which dealt with HPV vaccines, where an MA and SPC were obtained for a combination of HPV-6, HPV-11, HPV-16 and HPV-18 (Gardasil). Also there was an MA and SPC for a combination of HPV-16 and HPV-18 (Cervirax). Now Georgetown wanted an SPC for HPV-16 alone. According to the CJEU, the basic patent covered both the combination and the individual component and the products were regarded as separate innovative products. On the basis of this, Georgetown was allowed an SPC for HPV-16 alone.

From the last two decisions it can be concluded that if one has an SPC for product A, an SPC for product A+B will not be possible. If, however, an SPC was provided for A+B, an SPC for A will still be possible (provided that all products have been "covered" by the patent). It apparently matters in which sequence MAs and thus SPCs are applied for.

bart.jpg

Bart van Wezenbeek


V.O.Johan de Wittlaan 72517 JR The HagueThe NetherlandsTel: +31 70 416 67 11Fax: +31 70 416 67 99info@vo.euwww.vo.eu

more from across site and ros bottom lb

More from across our site

A 36-member team from Zhong Lun Law Firm, including six partners, will join the newly formed East IP Group
The Delhi High Court sided with Ericsson against Indian smartphone maker Lava, bringing the companies' nine-year dispute to a close
We provide a rundown of Managing IP’s news and analysis from the week, and review what’s been happening elsewhere in IP
Tennessee has passed the ELVIS Act, a law that fights against AI models that mimic the voice and likeness of music artists
Rob Stien, chief communications and public policy officer at InterDigital, says the EU has forgotten innovators while trying to solve an issue that doesn’t exist
As Australia’s Qantm IP leans towards being acquired by a private equity company, sources discuss what it could mean for IP firms
Law firms that are conscious of their role in society are more likely to win work, according to a survey of over 23,000 in-house professionals
Nghiem Xuan Bac Pham, managing partner of Vision & Associates, discusses opportunities created by the US-China rift as well as profitability issues facing IP practices
Douglas Leite and two of his colleagues were intrigued by Bhering Advogados’s mission to grow its patent litigation practice
Each week Managing IP speaks to a different IP practitioner about their life and career
Gift this article